- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT07948278
15-Year Follow-up of Protection and Immunity After Bivalent HPV Vaccination in Women (HPV Vaccine)
A 15-Year Follow-up Study of Long-Term Protection and Immunopersistence of an Escherichia Coli-Produced Bivalent HPV-16/18 Vaccine in Healthy Women Aged 18-45 Years
This study aims to evaluate the long-term protection provided by a bivalent HPV vaccine produced in Escherichia coli against specific clinical endpoints related to HPV types 16 and 18 in women aged 18-45 years, as well as the persistence of antibodies specific to these two HPV types.
Tutkimuksen yleiskatsaus
Tila
Yksityiskohtainen kuvaus
This observational study is a long-term follow-up of participants in the phase III clinical trial of a bivalent HPV 16/18 vaccine produced in Escherichia coli (HPV-PRO-003, NCT01735006). Women aged 18-45 years at enrollment in the original trial were randomly assigned to receive either the HPV vaccine or a hepatitis E vaccine. The follow-up study will retain the original vaccine and control groups. No additional study intervention will be administered.
Through 15 years after the first dose, this study aims to evaluate the long-term protection provided by the bivalent HPV vaccine against specific clinical endpoints associated with HPV types 16 and/or 18 and to assess the persistence of antibodies specific to HPV types 16 and 18.
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Yhteystiedot ja paikat
Opiskeluyhteys
- Nimi: Ting Wu
- Puhelinnumero: 0592-2880621
- Sähköposti: wuting.@xmu.edu.cn
Opiskelupaikat
-
-
Guangxi
-
Liuzhou, Guangxi, Kiina, 545007
- Liuzhou Center for Disease Control and Prevention
-
Ottaa yhteyttä:
- Haibo Wang, MSc
- Puhelinnumero: +86-772-3720738
- Sähköposti: lzcdcxmb@163.com
-
-
Hebei
-
Fengning, Hebei, Kiina, 068350
- Fengning Hospital of Traditional Chinese Medicine
-
Ottaa yhteyttä:
- Cuihong Dai, BSc
- Puhelinnumero: +86-314-8080327
- Sähköposti: wxn_cdfn@126.com
-
-
Henan
-
Qingpingjie, Henan, Kiina, 452370
- Xinmi Maternal and Child Health Hospital
-
Ottaa yhteyttä:
- Fengxian Zheng, BSc
- Puhelinnumero: +86-371-69833851
- Sähköposti: 513940819@qq.com
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
- Lapsi
- Aikuinen
- Vanhempi Aikuinen
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Näytteenottomenetelmä
Tutkimusväestö
The study population comprises women who received at least one dose of their assigned vaccine in the original phase III trial of the Escherichia coli-produced recombinant bivalent vaccine against human papillomavirus (HPV) types 16 and 18 (protocol HPV-PRO-003). To be eligible, women must not have received any HPV vaccine outside their original trial assignment since enrollment in that trial, including any subsequent catch-up doses given to control group participants. Participants retain their original group assignments (HPV vaccine group or hepatitis E vaccine control group).
Kuvaus
Inclusion Criteria:
- The participant took part in the phase III trial of the Escherichia coli-produced recombinant bivalent vaccine against human papillomavirus (HPV) types 16 and 18 (protocol HPV-PRO-003) and received at least one dose of the vaccine assigned to her in that trial.
- The participant has given informed consent and signed the consent form.
- The participant is able to complete all study procedures as required by the protocol.
Exclusion Criteria:
- Since enrollment in the original phase III trial, the participant has received any HPV vaccine other than the study vaccination assigned under the original trial protocol. This includes subsequent catch-up vaccination with the investigational vaccine among participants in the original control group, as well as receipt of any other licensed or unlicensed HPV vaccine.
- The participant had an invasive malignancy of the cervix, vagina, or vulva before enrollment in this follow-up study, or an abnormality detected at screening is confirmed to be an invasive malignancy at one of these sites by histopathological examination of a colposcopy-directed biopsy specimen.
- In the investigator's judgment, a medical, psychological, social, occupational, or other circumstance would interfere with the participant's ability to comply with the protocol or to provide written informed consent.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Havaintomallit: COHORT
- Aikanäkymät: PROSPECTIVE
Kohortit ja interventiot
Ryhmä/Kohortti |
Interventio / Hoito |
|---|---|
|
Vaccine group
Women assigned to the vaccine group in the original phase III trial who received at least one dose of the bivalent HPV 16/18 vaccine. Since enrollment in the original trial, they must not have received any HPV vaccine other than the study vaccine administered as specified in that trial's protocol. Participants must also meet all other eligibility criteria for this follow-up study. |
The bivalent HPV-16/18 vaccine was a mixture of two aluminum hydroxide adjuvant-absorbed recombinant L1 VLPs of HPV-16 and HPV-18 expressed in E. coli. A 0.5 ml dose of the bivalent HPV test vaccine comprised 40 μg of HPV-16 and 20 μg of HPV-18 L1 VLPs absorbed with 208 μg of aluminum adjuvant |
|
Control group
Women assigned to the control group in the original phase III trial who received at least one dose of control vaccine (hepatitis E vaccine). Since enrollment in the original trial, they must not have received any HPV vaccine other than vaccination specified in the original trial protocol. Participants must also meet all other eligibility criteria for this follow-up study. |
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
CIN2+, VIN2+, or VaIN2+ associated with HPV type 16 or 18 in the per-protocol population
Aikaikkuna: At months 156 and 180 after the first dose in the original trial
|
This endpoint includes grade 2 or worse cervical, vulvar, or vaginal intraepithelial neoplasia associated with either or both HPV types |
At months 156 and 180 after the first dose in the original trial
|
|
6-month persistent infection with HPV type 16 or 18 in the per-protocol population
Aikaikkuna: At months 156 and 180 after the first dose in the original trial
|
Infection with the same HPV type must persist for at least 6 months |
At months 156 and 180 after the first dose in the original trial
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
CIN1+, VIN1+, or VaIN1+ associated with HPV type 16 or 18
Aikaikkuna: At months 156 and 180 after the first dose in the original trial
|
This endpoint includes grade 1 or worse cervical, vulvar, or vaginal intraepithelial neoplasia associated with either or both HPV types |
At months 156 and 180 after the first dose in the original trial
|
|
CIN2+ associated with HPV type 16 or 18
Aikaikkuna: At months 156 and 180 after the first dose in the original trial
|
This endpoint includes grade 2 or worse cervical intraepithelial neoplasia associated with either or both HPV types |
At months 156 and 180 after the first dose in the original trial
|
|
VIN2+, or VaIN2+ associated with HPV type 16 or 18
Aikaikkuna: At months 156 and 180 after the first dose in the original trial
|
This endpoint includes grade 2 or worse vulvar, or vaginal intraepithelial neoplasia associated with either or both HPV types |
At months 156 and 180 after the first dose in the original trial
|
|
HPV-16-specific infection and/or lesion endpoints
Aikaikkuna: At months 156 and 180 after the first dose in the original trial
|
6-month persistent infection and grade 2 or worse cervical intraepithelial |
At months 156 and 180 after the first dose in the original trial
|
|
HPV-18-specific infection and/or lesion endpoints
Aikaikkuna: At months 156 and 180 after the first dose in the original trial
|
6-month persistent infection and grade 2 or worse cervical intraepithelial |
At months 156 and 180 after the first dose in the original trial
|
|
Type-specific infection and/or lesion endpoints associated with other high-risk HPV types, including HPV-31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68
Aikaikkuna: At months 156 and 180 after the first dose in the original trial
|
6-month persistent infection and grade 2 or worse cervical intraepithelial |
At months 156 and 180 after the first dose in the original trial
|
|
Type-specific seropositivity rates for HPV-16 and HPV-18 antibodies
Aikaikkuna: At months 156 and 180 after the first dose in the original trial
|
Percentage of participants seropositive for HPV-16 and HPV-18 antibodies |
At months 156 and 180 after the first dose in the original trial
|
|
Type-specific HPV-16 and HPV-18 antibody levels
Aikaikkuna: At months 156 and 180 after the first dose in the original trial
|
Serum antibody titers against HPV-16 and HPV-18 |
At months 156 and 180 after the first dose in the original trial
|
Muut tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
incident HPV-16 and/or HPV-18 infection
Aikaikkuna: At months 156 and 180 after the first dose in the original trial
|
Newly detected HPV-16 and/or HPV-18 DNA positivity |
At months 156 and 180 after the first dose in the original trial
|
Yhteistyökumppanit ja tutkijat
Sponsori
Tutkijat
- Opintojen puheenjohtaja: Jun Zhang, Xiamen University
- Päätutkija: Ting Wu, Xiamen University
Julkaisuja ja hyödyllisiä linkkejä
Yleiset julkaisut
- Zhao F, Chen Q, Zhao C, Nie L, Hu S, Yin J, Qiu L, Bi Z, Quan J, Li Y, Li M, Zhang X, Pan Q, Li C, Ke L, Liu X, Zheng F, Dai C, Wang Z, Kuang X, Jia X, Su Y, Huang S, Zhang Q, Huang W, Wei L, Zhang J, Wu T, Qiao Y, Xia N. Long-term efficacy and immunopersistence of an Escherichia coli-produced HPV-16/18 bivalent vaccine: an observational extension study following a randomised, double-blind Phase III clinical trial cohort. Lancet Reg Health West Pac. 2025 Aug 21;61:101668. doi: 10.1016/j.lanwpc.2025.101668. eCollection 2025 Aug.
- Zhao FH, Wu T, Hu YM, Wei LH, Li MQ, Huang WJ, Chen W, Huang SJ, Pan QJ, Zhang X, Hong Y, Zhao C, Li Q, Chu K, Jiang YF, Li MZ, Tang J, Li CH, Guo DP, Ke LD, Wu X, Yao XM, Nie JH, Lin BZ, Zhao YQ, Guo M, Zhao J, Zheng FZ, Xu XQ, Su YY, Zhang QF, Sun G, Zhu FC, Li SW, Li YM, Pan HR, Zhang J, Qiao YL, Xia NS. Efficacy, safety, and immunogenicity of an Escherichia coli-produced Human Papillomavirus (16 and 18) L1 virus-like-particle vaccine: end-of-study analysis of a phase 3, double-blind, randomised, controlled trial. Lancet Infect Dis. 2022 Dec;22(12):1756-1768. doi: 10.1016/S1473-3099(22)00435-2. Epub 2022 Aug 26.
- Qiao YL, Wu T, Li RC, Hu YM, Wei LH, Li CG, Chen W, Huang SJ, Zhao FH, Li MQ, Pan QJ, Zhang X, Li Q, Hong Y, Zhao C, Zhang WH, Li YP, Chu K, Li M, Jiang YF, Li J, Zhao H, Lin ZJ, Cui XL, Liu WY, Li CH, Guo DP, Ke LD, Wu X, Tang J, Gao GQ, Li BY, Zhao B, Zheng FX, Dai CH, Guo M, Zhao J, Su YY, Wang JZ, Zhu FC, Li SW, Pan HR, Li YM, Zhang J, Xia NS. Efficacy, Safety, and Immunogenicity of an Escherichia coli-Produced Bivalent Human Papillomavirus Vaccine: An Interim Analysis of a Randomized Clinical Trial. J Natl Cancer Inst. 2020 Feb 1;112(2):145-153. doi: 10.1093/jnci/djz074.
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Arvioitu)
Ensisijainen valmistuminen (Arvioitu)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
- Urogenitaaliset sairaudet
- Sukuelinten sairaudet
- Patologiset prosessit
- Neoplasmat
- Naisten virtsa- ja sukupuolielinten sairaudet
- Naisten virtsa- ja sukupuolielinten sairaudet ja raskauden komplikaatiot
- Sairauden ominaisuudet
- Infektiot
- Kohdun sairaudet
- Sukuelinten sairaudet, naiset
- Precancerous tilat
- Kohdun kohdunkaulan sairaudet
- Patologiset tilat, merkit ja oireet
- Pysyvä infektio
- Kohdun kohdunkaulan dysplasia
- Biologiset tuotteet
- Monimutkaiset seokset
- Rokotteet
Muut tutkimustunnusnumerot
- HPV-PRO-003-4
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
IPD-suunnitelman kuvaus
Proposals should be sent to the Principal Investigator. Proposals will be reviewed and approved by the study team.
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .